Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Subscribe To Our Newsletter & Stay Updated